







## Plenary 2: Global and regional enablers for the introduction of new TB vaccines

Manufacturer's Perspective

Rosane Cuber Guimarães Bio-Manguinhos - Fiocruz





SOMOS Inovação e produção a serviço do SUS

1111111111


### Detailed TB Vaccine Pipeline in clinical phase by platform and leading organization











Tuberculosis vaccines in clinical development worldwide, by phase and technology. Data source: AdisInsight (extracted July/24) and other sources (Looney et al., 2023; da Costa et al., 2024; StopTBPartnership (https://www.stoptb.org).

Source: Competitive Intelligence Office/Bio-Manguinhos, Fiocruz.






#### Challenges in regulatory process for new TB vaccines







#### **Harmonization of Regulatory Process**

Anvisa is considered a stringent NRA for Latin America, currently in the WHO prequalification process aims to achieve level 4.

ICH and PIC/S Member

ANVISA => Mercosul agreement

ANVISA => FDA "Mutual confidentiality agreement"

ANVISA => EMA "OPEN Program"

EMA = EU-M4ALL and PRIME tools









#### Main challenges and enablers for vaccine capacity building in developing countries

LMICs differ significantly in terms of industrial and technological capabilities, and all of them in different degrees face similar challenges. To assure timely and equitable access to vaccines these countries need FTO, technical assistance, access to adequate and long-term funding, and fair TT agreements













#### There is no one-size fits all solution

Partnering is not trivial. South-south and north-south collaboration has opportunities and challenges. Hybrid strategies, provided equitable access is granted, where health is a human right, and sustainable business models is a two-edged sword for all partners











# Thank you rosane@bio.fiocruz.br



